Squamous cell carcinoma of the bladder is a rare and aggressive subtype that accounts for roughly 2 to 5 percent of bladder cancers in Western countries, but it behaves quite differently from the far more common urothelial type that makes up the vast majority of cases. It tends to show up at a more advanced stage, responds poorly to conventional chemotherapy, and carries a worse prognosis stage for stage. The causes split along geographic lines: in much of Africa and the Middle East, a parasitic infection drives it, while in Western populations, chronic irritation of the bladder lining from catheters, recurrent infections, or other sources is the typical trigger.
How It Differs from the Usual Form of Bladder Cancer
When people hear “bladder cancer,” the disease in question is almost always urothelial carcinoma, which arises from the transitional cells lining the bladder interior. Squamous cell carcinoma (SCC) starts instead from flat squamous cells, a cell type not normally abundant in a healthy bladder. The bladder lining can transform into squamous tissue over years of chronic inflammation or irritation, a process called squamous metaplasia. That transformed tissue then carries a risk of becoming cancerous.
The practical difference matters because SCC of the bladder is more locally aggressive. It tends to invade the muscle wall of the bladder before it is detected, but it spreads to distant lymph nodes and organs somewhat less readily than urothelial carcinoma in its early stages. This combination of deep local invasion and late presentation makes it a difficult cancer to catch early and treat effectively. In one large Egyptian series, SCC represented 59 percent of cystectomy specimens, reflecting how dominant the disease was in regions with endemic schistosomiasis.1PubMed. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment In Western countries, it remains uncommon enough that many urologists will see only a handful of cases in a career.
Causes and Risk Factors
The thread connecting virtually every known risk factor for bladder SCC is chronic irritation and inflammation of the bladder wall. The specific irritants vary by geography and individual circumstances, but the end result is the same: years of damage push normal bladder lining cells toward squamous transformation, and eventually some of those cells become malignant.
Schistosomiasis
In regions of Africa, the Middle East, and parts of South America and Southeast Asia, infection with the parasitic worm Schistosoma haematobium is the leading cause. The parasite deposits eggs in the bladder wall, provoking decades of chronic inflammation. This infection is considered the second most burdensome tropical pathogen after malaria.2PubMed Central. Epidemiology of Bladder Cancer Research into the molecular mechanisms has shown that the immune response to the parasite shifts the body toward a pattern of inflammation that, over time, promotes high-grade bladder cancer through complement activation and sustained oxidative stress.3PubMed. Insight into the molecular basis of Schistosoma haematobium-induced bladder cancer through urine proteomics In schistosomiasis-driven SCC, patients are typically younger, often diagnosed in their fifties, and the disease is about five times more common in men.1PubMed. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment
Long-Term Catheterization
In Western countries, where schistosomiasis is not a factor, chronic catheter use is one of the best-recognized risk factors. People with spinal cord injuries who require long-term indwelling catheters face a markedly elevated risk. One prospective study of spinal cord injury patients catheterized for at least ten years found SCC in 8 percent.4Journal of Urology. Incidence of Squamous Cell Carcinoma in Patients With Long-term Catheter Drainage The type of catheter matters: SCC was considerably more common among patients with indwelling urethral or suprapubic catheters than among those using intermittent catheterization or condom drainage.5PubMed. Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury The constant physical irritation and recurrent infections that accompany permanent catheters are what drive the transformation.
Recurrent Infections, Smoking, and Other Irritants
A UK study examining risk factors in bladder SCC patients found that over half had at least one identifiable risk factor. About 28 percent were current or former smokers, 20 percent had a documented history of recurrent urinary tract infections, roughly 14 percent had a history of catheter use, and 10 percent had a neurogenic bladder.6PubMed Central. Risk factors for development of primary bladder squamous cell carcinoma Smoking is a well-established driver of bladder cancer overall, with about half of all bladder cancer cases in the United States attributed to cigarette smoking and other known carcinogens. But its role in squamous cell bladder cancer specifically, while real, is somewhat overshadowed by the chronic-irritation pathway. Bladder stones, chronic cystitis, and other conditions that keep the bladder wall inflamed for years can also contribute.
Symptoms and How It Is Diagnosed
The most common symptom by far is blood in the urine. In a study of 42 patients with bladder SCC, roughly 71 percent presented with hematuria as their initial complaint.7PubMed. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer A separate analysis of 45 cases confirmed this pattern, with the majority of patients who reported any symptoms presenting with blood in their urine, and the remainder describing other lower urinary tract complaints such as urgency, frequency, or pain during urination.8The American Journal of Surgical Pathology. Squamous Cell Carcinoma of the Bladder: A Clinicopathologic Analysis of 45 Cases Some patients experience pelvic pain or weight loss, but those tend to signal more advanced disease.
The diagnostic workup generally starts with cystoscopy and urine cytology, the same tools used for all suspected bladder cancers. Cystoscopy lets the doctor look directly inside the bladder and biopsy suspicious areas. Urine cytology, which checks shed cells for signs of cancer, is quite specific but misses a lot of cases, especially lower-grade tumors.9PubMed Central. Urine cytology and adjunct markers for detection and surveillance of bladder cancer CT urography adds another layer, and in one large study of patients investigated for blood in their urine, it achieved very high sensitivity for detecting bladder tumors when used alongside cystoscopy.10PubMed. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology
The tricky part comes after the biopsy. Pathologists must distinguish pure squamous cell carcinoma from urothelial carcinoma that has developed areas of squamous differentiation, since these are treated and tracked somewhat differently. A panel of specific tissue stains can help sort this out: certain markers like CK5/14 light up strongly in pure SCC but are less prominent in urothelial tumors, while markers like CK7 and uroplakin III are more characteristic of urothelial origin.11PubMed. Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer Getting this distinction right matters because pure SCC and urothelial carcinoma with squamous features carry different treatment implications.12PubMed. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract
Treatment
Radical cystectomy, the complete surgical removal of the bladder, is the backbone of treatment for squamous cell bladder cancer. Multiple studies have consistently shown that surgery provides the best survival outcomes. In a large population-level analysis of over 5,600 patients with bladder SCC, median survival was 13 months overall, but patients who received surgery alone had a five-year survival rate of about 35 percent, compared with far worse outcomes for those treated with chemotherapy or radiation without surgery.13Journal of Surgical Oncology. Squamous cell carcinoma of the bladder: Causes, symptoms, and outlook A comparative effectiveness study reinforced this finding: radical cystectomy with or without chemotherapy was associated with substantially better survival than any non-surgical approach.14PubMed. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder
Chemotherapy is where bladder SCC diverges most sharply from the urothelial type. Standard cisplatin-based chemotherapy regimens, which meaningfully shrink urothelial tumors before surgery in many patients, appear to have little effect on squamous cell carcinoma. A multi-institutional study found that among patients receiving neoadjuvant chemotherapy before cystectomy, those with SCC had a median cancer-specific survival of 33 months compared with 116 months for pure urothelial carcinoma, with SCC showing significantly lower rates of tumor downstaging. The researchers concluded that SCC appeared insensitive to traditional chemotherapy regimens.15PubMed Central. Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant
Radiation therapy has also shown limited effectiveness as a standalone treatment. An older study of radical radiotherapy for bladder SCC reported a complete regression rate of about 42 percent, but three-year survival was only around 18 percent.16PubMed. Radiotherapy for squamous carcinoma of the urinary bladder That said, preoperative radiation combined with surgery may improve outcomes compared with radiation alone, a finding noted in a systematic review of the disease.17PubMed Central. Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches Overall, the evidence points clearly toward surgery as the most effective intervention, with adjunctive therapies playing a supporting role at best.
Survival and Outlook
The prognosis for bladder SCC depends heavily on the stage at diagnosis and whether the patient can undergo radical cystectomy. An early study of 33 patients treated with radical cystectomy reported a five-year survival rate of 48 percent, with outcomes closely tracking pathologic stage and tumor grade. The authors noted that survival was actually better than for corresponding stages of urothelial carcinoma, suggesting that when caught and surgically treated, the tumor’s local aggressiveness can be addressed.18PubMed. Squamous carcinoma of the bladder: treatment by radical cystectomy More recent data from a propensity-matched analysis tells a more sobering story when SCC is compared against urothelial carcinoma across all comers: five-year overall survival was about 43 percent for SCC versus nearly 60 percent for pure urothelial carcinoma after adjusting for baseline differences.19PubMed Central. The prognostic impact of squamous differentiation in bladder cancer after radical cystectomy
A key finding from the survival literature is that the disadvantage of SCC is most pronounced when surgery is not performed. One population-based analysis found that SCC was an independent predictor of higher cancer-specific mortality across all stages on multivariable analysis, with hazard ratios ranging from about 1.4 to nearly 2.0 depending on the stage.20PubMed. Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities Another study clarified this further: among patients with early-stage disease (stage I or II) who underwent cystectomy, the survival disadvantage of SCC disappeared. It was only when early-stage patients did not receive cystectomy, or when the disease was already advanced, that SCC carried worse outcomes than the urothelial type.21PubMed. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? The message is consistent: early surgery is the single most important factor in long-term survival.
Immunotherapy and Emerging Research
The poor response to chemotherapy has pushed researchers to look at immunotherapy as a potential option. Immune checkpoint inhibitors targeting PD-1 and PD-L1 have transformed treatment for advanced urothelial carcinoma in recent years, and there is growing interest in whether they might help patients with the squamous subtype as well. The rationale is there: studies examining PD-L1 expression in bladder SCC have found meaningful levels of the protein in a subset of tumors. One study found that depending on the antibody used, positive PD-L1 staining on immune cells ranged widely, and estimated that up to about 20 percent of SCC patients might qualify for pembrolizumab under the criteria used for first-line urothelial cancer treatment.22PubMed Central. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
More recent molecular profiling has identified that bladder SCC tends to fall into a basal/squamous molecular subtype with frequent activation of the EGFR pathway and alterations in TP53 and RB1, which could open the door to targeted therapies. A separate study characterizing the tumor-immune environment in squamous bladder cancer found that tumors with a “hot” immune phenotype and strong PD-L1 expression might represent a particularly promising subgroup for checkpoint inhibitor therapy.23PubMed Central. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer These are early-stage findings, though. No large randomized trials have specifically tested immunotherapy in bladder SCC, so the evidence remains preliminary. For now, checkpoint inhibitors are used on a case-by-case basis, often when the cancer has progressed after surgery or when a patient is not a candidate for radical cystectomy.
Disparities in Who Gets Diagnosed Late
Bladder cancer in general has well-documented disparities in how early it is caught, and these disparities are especially consequential for aggressive subtypes like SCC, where late diagnosis dramatically worsens the prognosis. A large analysis of national cancer data found that Black patients, women, and uninsured individuals were significantly more likely to be diagnosed at advanced stages. Black patients had higher odds of being diagnosed with muscle-invasive, locally advanced, or metastatic disease compared with earlier-stage diagnosis. Uninsured patients faced even steeper odds of late-stage diagnosis.24PubMed Central. Racial inequity and other social disparities in the diagnosis and management of bladder cancer Older age, lower income, lower educational attainment, and rural residence were also associated with delayed diagnosis.
These delays matter enormously for bladder SCC because, as the survival data show, the window for curative surgery is narrow. People in lower-income areas face greater exposure to carcinogens, have less access to screening, and may experience less awareness of warning signs like blood in the urine, all of which contribute to later presentation.25JNCI Cancer Spectrum. Socioeconomic disparities and bladder cancer stage at diagnosis: a statewide cohort analysis For a cancer where early cystectomy essentially erases the survival gap with urothelial carcinoma, anything that delays that surgery costs lives disproportionately among already disadvantaged populations.
How Schistosomiasis Control Changed an Entire Country’s Cancer Profile
Perhaps the most dramatic illustration of how closely bladder SCC is tied to its causes comes from Egypt. For most of the twentieth century, bladder cancer was the most common cancer in the country, and the vast majority of cases were squamous cell carcinoma driven by endemic schistosomiasis. Mass treatment campaigns and improvements in sanitation began reducing schistosomiasis rates in the 1980s and 1990s. As infection rates fell, the profile of bladder cancer in Egypt shifted: urothelial carcinoma began replacing SCC as the dominant subtype, mirroring what was already seen in Western countries. It is a rare example of a public health campaign against a parasitic disease producing a measurable change in a nation’s cancer epidemiology.26PubMed. Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt The transformation underscores the central role of chronic inflammation in driving this particular cancer. Remove the source of irritation, and the cancer recedes along with it.